Clinicopathologic features of undetected dysplasia found in total colectomy or proctocolectomy specimens of patients with inflammatory bowel disease.
colectomy
dysplasia
inflammatory bowel disease
nonconventional
primary sclerosing cholangitis
Journal
Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
revised:
04
04
2022
received:
26
02
2022
accepted:
28
04
2022
pubmed:
30
4
2022
medline:
22
7
2022
entrez:
29
4
2022
Statut:
ppublish
Résumé
It remains controversial as to whether targeted biopsies should completely replace random biopsies for dysplasia surveillance in patients with inflammatory bowel disease (IBD). Several histologic patterns of nonconventional dysplasia have been described in IBD. This study aimed to investigate the rate and clinicopathologic features of dysplastic lesions found in total colectomy or proctocolectomy specimens that were undetected on prior colonoscopy. The study analyzed 207 consecutive IBD patients who underwent a total colectomy or proctocolectomy and had at least one high-definition colonoscopy prior to colectomy. Dysplasia found in the colectomy specimens was classified as undetected, only when there was no corresponding site of dysplasia detected on previous colonoscopic biopsies. Twenty-seven (13%) patients had 49 undetected dysplastic lesions found only at colectomy, while 22 (11%) had 31 previously detected dysplastic lesions only. The remaining 158 (76%) patients had no dysplasia. A greater proportion of the undetected (19%) or previously detected (23%) dysplasia group had concurrent primary sclerosing cholangitis compared with only 3% in the group without dysplasia (P < 0.001). The undetected dysplastic lesions were more likely to have nonconventional dysplastic features (76%), low-grade dysplasia (94%), and a flat/invisible gross appearance (73%) compared with the previously detected dysplastic lesions (13%, 68%, and 48%, respectively) (P < 0.05). Almost all patients with undetected dysplasia (93%) had a colonoscopy within 1 year of colectomy. The rate of undetected dysplasia is not insignificant (13%), suggesting that increased random biopsies may improve the rate of dysplasia detection, including nonconventional dysplasia.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
183-191Subventions
Organisme : UCSF Department of Pathology
ID : Not applicable
Informations de copyright
© 2022 John Wiley & Sons Ltd.
Références
Ekbom A, Helmick C, Zack M et al. Ulcerative colitis and colorectal cancer. A population-based study. N. Engl. J. Med. 1990; 323; 1228-1233.
Ekbom A, Helmick C, Zack M et al. Increased risk of large-bowel cancer in Crohn's disease with colonic involvement. Lancet 1990; 336; 357-359.
Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin. Gastroenterol. Hepatol. 2012; 10; 639-645.
Lutgens MW, van Oijen MG, van der Heijden GJ et al. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm. Bowel Dis. 2013; 19; 789-799.
Rubin DT, Ananthakrishnan AN, Siegel CA et al. ACG clinical guideline: ulcerative colitis in adults. Am. J. Gastroenterol. 2019; 114; 384-413.
Farraye FA, Odze RD, Eaden J et al. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010; 138; 746-774.
American Society for Gastrointestinal Endoscopy Standards of Practice Committee, Shergill AK, Lightdale JR et al. The role of endoscopy in inflammatory bowel disease. Gastrointest. Endosc. 2015; 81; 1101-21.e1-1101-21.e13.
Rubin CE, Haggitt RC, Burmer GC et al. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 1992; 103; 1611-1620.
Farraye FA, Odze RD, Eaden J et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010; 138; 738-745.
Leighton JA, Shen B, Baron TH et al. ASGE guideline: endoscopy in the diagnosis and treatment of inflammatory bowel disease. Gastrointest. Endosc. 2006; 63; 558-565.
Kaltenbach T, Sandborn WJ. Endoscopy in inflammatory bowel disease: advances in dysplasia detection and management. Gastrointest. Endosc. 2017; 86; 962-971.
Rutter MD, Saunders BP, Wilkinson KH et al. Most dysplasia in ulcerative colitis is visible at colonoscopy. Gastrointest. Endosc. 2004; 60; 334-339.
Rubin DT, Rothe JA, Hetzel JT et al. Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? Gastrointest. Endosc. 2007; 65; 998-1004.
Blonski W, Kundu R, Lewis J et al. Is dysplasia visible during surveillance colonoscopy in patients with ulcerative colitis? Scand. J. Gastroenterol. 2008; 43; 698-703.
Watanabe T, Ajioka Y, Mitsuyama K et al. Comparison of targeted vs random biopsies for surveillance of ulcerative colitis-associated colorectal cancer. Gastroenterology 2016; 151; 1122-1130.
Laine L, Kaltenbach T, Barkun A et al. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastrointest. Endosc. 2015; 81; 489-501.
Murthy SK, Feuerstein JD, Nguyen GC et al. AGA clinical practice update on endoscopic surveillance and management of colorectal dysplasia in inflammatory bowel diseases: expert review. Gastroenterology 2021; 161; 1043-1051.e4.
Rabinowitz LG, Kumta NA, Marion JF. Beyond the SCENIC route: updates in chromoendoscopy and dysplasia screening in patients with inflammatory bowel disease. Gastrointest. Endosc. 2022; 95; 30-37.
Van Assche G, Dignass A, Bokemeyer B et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J. Crohns Colitis 2013; 7; 1-33.
Ullman T, Croog V, Harpaz N et al. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology 2003; 125; 1311-1319.
Tsai JH, Rabinovitch PS, Huang D et al. Association of aneuploidy and flat dysplasia with development of high-grade dysplasia or colorectal cancer in patients with inflammatory bowel disease. Gastroenterology 2017; 153; 1492-1495.
Choi CH, Rutter MD, Askari A et al. Forty-year analysis of colonoscopic surveillance program for neoplasia in ulcerative colitis: an updated overview. Am. J. Gastroenterol. 2015; 110; 1022-1034.
Connell WR, Lennard-Jones JE, Williams CB et al. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology 1994; 107; 934-944.
Friedman S, Rubin PH, Bodian C et al. Screening and surveillance colonoscopy in chronic Crohn's colitis. Gastroenterology 2001; 120; 820-826.
Hata K, Watanabe T, Kazama S et al. Earlier surveillance colonoscopy programme improves survival in patients with ulcerative colitis associated colorectal cancer: results of a 23-year surveillance programme in the Japanese population. Br. J. Cancer 2003; 89; 1232-1236.
Hu AB, Burke KE, Kochar B et al. Yield of random biopsies during colonoscopies in inflammatory bowel disease patients undergoing dysplasia surveillance. Inflamm. Bowel Dis. 2021; 27; 779-786.
Moussata D, Allez M, Cazals-Hatem D et al. Are random biopsies still useful for the detection of neoplasia in patients with IBD undergoing surveillance colonoscopy with chromoendoscopy? Gut 2018; 67; 616-624.
Eluri S, Parian AM, Limketkai BN et al. Nearly a third of high-grade dysplasia and colorectal cancer is undetected in patients with inflammatory bowel disease. Dig. Dis. Sci. 2017; 62; 3586-3593.
Choi WT, Yozu M, Miller G et al. Non-conventional dysplasia in patients with inflammatory bowel disease and colorectal carcinoma: a multicenter clinicopathologic study. Mod. Pathol. 2020; 33; 933-943.
Lee H, Rabinovitch PS, Mattis AN et al. Non-conventional dysplasia in inflammatory bowel disease is more frequently associated with advanced neoplasia and aneuploidy than conventional dysplasia. Histopathology 2021; 78; 814-830.
Wen KW, Umetsu SE, Goldblum JR et al. DNA flow cytometric and interobserver study of crypt cell atypia in inflammatory bowel disease. Histopathology 2019; 75; 578-588.
Pereira D, Kővári B, Brown I et al. Non-conventional dysplasias of the tubular gut: a review and illustration of their histomorphological spectrum. Histopathology 2021; 78; 658-675.
Choi WT. Non-conventional dysplastic subtypes in inflammatory bowel disease: a review of their diagnostic characteristics and potential clinical implications. J Pathol Transl Med 2021; 55; 83-93.
Choi WT, Salomao M, Zhao L et al. Hypermucinous, goblet cell deficient, and crypt cell dysplasias in inflammatory bowel disease are often associated with flat/invisible endoscopic appearance and advanced neoplasia on follow-up. J. Crohns Colitis 2022; 16; 98-108.
Choi WT, Kővári BP, Lauwers GY. The significance of flat/invisible dysplasia and nonconventional dysplastic subtypes in inflammatory bowel disease: a review of their morphologic, clinicopathologic, and molecular characteristics. Adv. Anat. Pathol. 2022; 29; 15-24.
Andersen SN, Lovig T, Clausen OP et al. Villous, hypermucinous mucosa in long standing ulcerative colitis shows high frequency of K-ras mutations. Gut 1999; 45; 686-692.
Gui X, Köbel M, Ferraz JG et al. Histological and molecular diversity and heterogeneity of precancerous lesions associated with inflammatory bowel diseases. J. Clin. Pathol. 2020; 73; 391-402.
Riddell RH, Goldman H, Ransohoff DF et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum. Pathol. 1983; 14; 931-968.
Wanders LK, Cordes M, Voorham Q et al. IBD-associated dysplastic lesions show more chromosomal instability than sporadic adenomas. Inflamm. Bowel Dis. 2020; 26; 167-180.
Soetikno RM, Lin OS, Heidenreich PA et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest. Endosc. 2002; 56; 48-54.
Torres J, Pineton de Chambrun G, Itzkowitz S et al. Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease. Aliment. Pharmacol. Ther. 2011; 34; 497-508.
Zheng HH, Jiang XL. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis of 16 observational studies. Eur. J. Gastroenterol. Hepatol. 2016; 28; 383-390.
Cordes F, Laumeyer T, Gerß J et al. Distinct disease phenotype of ulcerative colitis in patients with coincident primary sclerosing cholangitis: evidence from a large retrospective study with matched cohorts. Dis. Colon Rectum 2019; 62; 1494-1504.
Brentnall TA, Haggitt RC, Rabinovitch PS et al. Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1996; 110; 331-338.
Shetty K, Rybicki L, Brzezinski A et al. The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am. J. Gastroenterol. 1999; 94; 1643-1649.
Navaneethan U, Kochhar G, Venkatesh PG et al. Random biopsies during surveillance colonoscopy increase dysplasia detection in patients with primary sclerosing cholangitis and ulcerative colitis. J. Crohns Colitis 2013; 7; 974-981.